Data on migration of the non-invasive breast cancer cell line, MCF-7 treated with Bevacizumab using Real Time Cell Analyzer (RTCA)
Layal EL-Hajjar,
Abdullah Shaito,
Nour Jalaleddine,
Kazem Zibara,
Jalal M. Kazan,
Jamal El-Saghir,
Marwan El-Sabban
Affiliations
Layal EL-Hajjar
Department of Biological and Environmental Sciences, Faculty of Science, Beirut Arab University, Beirut, Lebanon
Abdullah Shaito
Department of Biological and Environmental Sciences, Faculty of Science, Beirut Arab University, Beirut, Lebanon
Nour Jalaleddine
Department of Biological and Chemical Sciences, Faculty of Arts and Sciences, Lebanese International University, Beirut, Lebanon
Kazem Zibara
ER045 – Laboratory of Stem Cells, PRASE, Biology Department, Faculty of Sciences, Lebanese University, Beirut, Lebanon
Jalal M. Kazan
Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
Jamal El-Saghir
Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
Marwan El-Sabban
Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon; Correspondence to: Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut, Lebanon.
Bevacizumab or Avastin® (Av), the recombinant antibody targeting VEGF, improves progression-free but not overall survival of metastatic breast cancer patients due to development of Av resistance. We showed that Av-therapy-induced inflammatory microenvironment contributes to the refractoriness to Av treatment. Here we present data regarding the effect of Av treatment on migration of a non-invasive breast cancer cell line, MCF-7. The data presented hereis related to the research article “Bevacizumab induces inflammation in MDA-MB-231 breast cancer cell line and in a mouse model” (Hajjar et al., 2018). Keywords: Bevacizumab, MCF-7, Migration, RTCA
